GlassScriptPhysician profile
Kyle Zakkar
NPI 1083104525
$7,837.63
in general payments reported to CMS, 2019-2025
19 companies · $3,564 in 2025
The $3,564 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $301 · 2022: $726 · 2023: $1,029 · 2024: $2,217 · 2025: $3,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,681 · Education: $2,500 · Food and Beverage: $1,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,681.42 |
| Education | $2,500.00 |
| Food and Beverage | $1,629.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,579.30 | 2024-2025 | |
| Olympus Corporation of The Americas | $1,783.76 | 2024 | Single Use Suction Valve (Sterile), Spiration Valve System, Vizishot 2 Flex |
| Glaxosmithkline, LLC. | $605.17 | 2021-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $422.81 | 2022-2024 | Breztri, Fasenra, Imfinzi |
| Inari Medical, INC. | $303.92 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Genzyme Corporation | $238.39 | 2022-2023 | |
| Pulmonx Corporation | $178.70 | 2021 | |
| Gilead Sciences, INC. | $152.95 | 2022-2023 | Veklury |
| Axsome Therapeutics, INC. | $147.47 | 2023 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2023 | |
| Olympus America INC. | $109.76 | 2023 | Spiration Valve System |
| Edwards Lifesciences Corporation | $48.28 | 2022-2024 | Hemosphere |
| Abbvie INC. | $27.92 | 2024 | |
| Grifols USA, LLC | $26.11 | 2024 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $23.20 | 2024 | Acthar |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $17.83 | 2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $17.65 | 2024 | Dificid, Zerbaxa, Recarbrio |
| Insmed, INC. | $15.56 | 2022 | |
| Amgen INC. | $13.85 | 2025 | Tavneos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Zakkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.